VHT vs XLV

Key Takeaways

• VHT offers broader exposure across ~412 holdings spanning large-, mid-, and small-cap U.S. healthcare stocks via the MSCI US Investable Market Health Care 25/50 Index, contrasting XLV's concentrated ~60 large-cap S&P 500 healthcare constituents.
• Both ETFs maintain ultra-low expense ratios—VHT at 0.09% and XLV at 0.08%—ensuring cost efficiency for long-term sector exposure.
• XLV exhibits higher concentration risk with top 10 holdings comprising ~58%, led by LLY (~14%), while VHT's top 10 account for ~50% with more balanced diversification.
• XLV demonstrates superior liquidity with significantly higher average daily volume, appealing for tactical trades, whereas VHT suits buy-and-hold strategies emphasizing growth potential from smaller names.
• Healthcare sector's defensive profile shines amid macro uncertainty, with both ETFs showing lower volatility relative to broader markets in recent cycles.
• XLV's large-cap focus provides steadier risk-adjusted returns, while VHT captures mid/small-cap upside tied to innovation cycles.

Introduction

Comparing VHT and XLV highlights nuanced choices within U.S. healthcare ETFs, both tracking passive indices but differing in scope and structure. These funds offer alternative exposures to the resilient healthcare sector, which benefits from aging demographics, innovation in biotech and pharmaceuticals, and defensive qualities during economic rotations. VHT provides comprehensive market-cap coverage for diversified growth, while XLV focuses on S&P 500 stalwarts for concentrated stability. Amid recent sector momentum from earnings strength and policy tailwinds, investors weigh VHT's breadth against XLV's liquidity and mega-cap tilt in portfolio allocation.

Vanguard Health Care ETF (VHT) Overview

The Vanguard Health Care ETF (VHT) seeks to track the MSCI US Investable Market Health Care 25/50 Index, encompassing large-, mid-, and small-cap U.S. companies in healthcare per GICS classification. Launched in 2004 with ~$20.3 billion in AUM, VHT holds approximately 412 stocks, promoting broad diversification. Top holdings include LLY (12.7%), JNJ (8.2%), ABBV (6.0%), MRK (4.2%), and UNH (4.0%), with the top 10 comprising ~50% of assets.

Sector allocations emphasize pharmaceuticals (32%), biotechnology (23%), and health care equipment (18%). The expense ratio is a low 0.09%, with a turnover of ~4% reflecting quarterly rebalancing aligned to the index. As a passive, full-replication fund (sampling if needed), VHT distinguishes itself through extensive coverage of innovative mid/small-caps alongside blue-chips, minimizing tracking error via Vanguard's efficient indexing.

State Street Health Care Select Sector SPDR ETF (XLV) Overview

The State Street Health Care Select Sector SPDR ETF (XLV), dating to 1998 with ~$39 billion AUM, tracks the Health Care Select Sector Index, a float-adjusted market-cap subset of S&P 500 healthcare firms. Holding ~60 stocks, it targets pharmaceuticals, providers, equipment, biotech, life sciences, and technology. Top holdings feature LLY (14.3%), JNJ (10.7%), ABBV (7.3%), MRK (5.3%), and UNH (4.6%), with top 10 at ~58%.

Allocations skew to pharmaceuticals (37%), equipment/supplies (19%), and biotech (19%). At 0.08% expense ratio and ~2% turnover, XLV employs replication for precise tracking, rebalanced per S&P methodology. Its large-cap focus ensures high liquidity and lower volatility, positioning it as a tactical tool for sector rotation.

Industry and Thematic Backdrop

The U.S. healthcare sector navigates a dynamic environment shaped by aging demographics driving demand for services and therapies, alongside AI-accelerated drug discovery and outpatient expansion. Macro catalysts include moderating inflation easing cost pressures, potential policy shifts on drug pricing, and resilient capital flows into defensive assets amid geopolitical tensions. Recent inflows reflect rotation from high-valuation tech toward healthcare's steady earnings. Risks encompass regulatory scrutiny on pharma pricing, workforce shortages, and elevated capital costs, yet structural tailwinds like biotech innovation and telemedicine growth sustain sector appeal across market cycles.

Performance and Positioning Comparison

In recent weeks and months, both ETFs have exhibited relative stability amid broader market rotations, with YTD drawdowns around 1-2% versus sharper declines elsewhere. XLV's large-cap emphasis has edged VHT in steadiness, buoyed by mega-cap earnings from LLY and JNJ, while VHT benefits from mid-cap biotech momentum. Over recent cycles, XLV shows marginally lower volatility due to S&P 500 liquidity, contrasting VHT's higher beta from smaller holdings. Positioning ties to interest rate expectations favoring defensives and sector rotation dynamics, with both capturing healthcare's outperformance versus cyclicals.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots under prevailing market conditions. Amid hundreds of bots analyzing thousands of tickers across varied timeframes and strategies—from momentum and mean reversion to volatility-based approaches— this curated section highlights those with the strongest recent track records, often delivering double-digit returns over short horizons. Performance metrics emphasize win rates, profit factors, and drawdown control, tailored to equities, ETFs, forex, and crypto. Investors can explore, backtest, and deploy these bots for automated trading. Visit the page to discover leading performers and elevate your strategy with AI precision.

Tickeron AI Verdict

Tickeron’s AI currently favors XLV for its superior liquidity, slightly lower costs, large-cap stability, and concentrated exposure to high-momentum leaders like LLY, aligning with ongoing sector rotation and defensive momentum. While VHT's diversification offers long-term growth potential, XLV's risk-adjusted profile and trend consistency provide a probabilistic edge in the present environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations